Patient-Reported Outcomes and Their Role in the Assessment of Rheumatoid Arthritis

PharmacoEconomics

Volumn 22, Issue 1, 2004, Pages 27-38

  Lubeck, Deborah P ^a,b,c  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; METHOTREXATE;

CLINICAL EXAMINATION; CLINICAL TRIAL; DISEASE SEVERITY; EMOTION; GASTROINTESTINAL TOXICITY; HUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SOCIAL ASPECT; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 1442352155     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422001-00004     Document Type: Review

References (96)

1. Anonymous. The burden of rheumatoid arthritis. Based on a presentation by Frederick Wolfe, MD. Am J Manag Care 1999; 5 Suppl. 14: S852-9; discussion S866-9
2. Harris Jr ED. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990; 322 (18): 1277-89
3. Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997; 24 (1): 43-8
4. WHO, The First Ten Years of the World Health Organization. 1958, Geneva: World Health Organization
5. Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991; 18 (9): 1298-306
6. Callahan LF, Brooks RH, Summey JA, Pincus T. Quantitative pain assessment for routine care of rheumatoid arthritis patients, using a pain scale based on activities of daily living and a visual analog pain scale. Arthritis Rheum 1987; 30 (6): 630-6
7. MacKinnon JR, Avison WR, McCain GA. Pain and functional limitations in individuals with rheumatoid arthritis. Int J Rehabil Res 1994; 17 (1): 49-59
8. Kazis LE, Meenan RF, Anderson JJ. Pain in the rheumatic diseases. Investigation of a key health status component. Arthritis Rheum 1983; 26 (8): 1017-22
9. Nichol MB, Harada AS. Measuring the effects of medication use on health-related quality of life in patients with rheumatoid arthritis. A review. Pharmacoeconomics 1999; 16 (5 Pt 1): 43348
10. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35 (5): 498-502
11. Felts W, Yelin E. The economic impact of the rheumatic diseases in the United States. J Rheumatol 1989; 16 (7): 867-84
12. Yelin E. Arthritis. The cumulative impact of a common chronic condition. Arthritis Rheum 1992; 35 (5); 489-97
13. Yelin EH. Musculoskeletal conditions and employment. Arthritis Care Res 1995; 8 (4): 311-7
14. Katz PP, Yelin E. Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis. J Rheumatol 1993; 20 (5): 790-6
15. Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol 1995; 22 (4): 639-43
16. Fifield J, McQuillan J, Tennen H, et al. History of affective disorder and the temporal trajectory of fatigue in rheumatoid arthritis. Ann Behav Med 2001; 23 (1): 3441
17. Singh G, Lingala B, Bennett M, Wanke L, Singh A. Epidemiology of fatigue in rheumatoid arthritis: prevalence and clinical correlates. Presented at EULAR 2003, Lisbon, Portugal
18. Singh G, Lingala B, Bennett M, Wanke L, Singh A. Fatigue in rheumatoid arthritis: significant correlation with direct medical costs and missed days of work. Presented at EULAR 2003, Lisbon, Portugal
19. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996; 23 (8): 1407-17
20. Lorish CD, Abraham N, Austin J, Bradley LA, Alarcon GS. Disease and psychosocial factors related to physical functioning in rheumatoid arthritis. J Rheumatol 1991; 18 (8): 1150-7
21. Belza BL, Henke CJ, Yelin EH, Epstein WV, Gillis CL. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 1993; 42 (2): 93-9
22. Riemsma RP, Rasker JJ, Taal E, Griep EN, Wouters JM, Wiegman O. Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support. Br J Rheumatol 1998; 37 (10): 1042-6
23. Smith TW, Peck JR, Ward JR. Helplessness and depression in rheumatoid arthritis. Health Psychol 1990; 9 (4): 377-89
24. Callahan LF, Cordray DS, Wells G, Pincus T. Formal education and five-year mortality in rheumatoid arthritis: Mediation by helplessness scale scores. Arthritis Care Res 1996; 9 (6): 463-72
25. Mikuls TR, Saag KG. Comorbidity in rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27 (2): 283-303
26. Gabriel S, Crowson C, O'Fallon W. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999; 26: 2529-33
27. Verbrugge LM, Gates DM, Ike RW. Risk factors for disability among U.S. adults with arthritis. J Clin Epidemiol 1991; 44 (2): 167-82
28. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36 (6): 72940
29. Fitzpatrick R, Ziebland S, Jenkinson C, Mowat A. A comparison of the sensitivity to change of several health status instruments in rheumatoid arthritis. J Rheumatol 1993; 20 (3): 429-36
30. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993; 118 (8): 622-9
31. Guyatt GH, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987; 40 (2): 171-8
32. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27 Suppl. 3: S217-32
33. Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of life in clinical trials. CMAJ 1986; 134 (8): 889-95
34. Ware Jr JE. The status of health assessment 1994. Annu Rev Public Health 1995; (16): 327-54
35. Cheah SY, Clark C, Goldberg L, Li Wan Po A, Phillips R. Outcome measures, pooled index and quality of life instruments in rheumatoid arthritis. J Clin Pharm Ther 1996; 21 (5): 297-316
36. de Jong Z, van der Heijde D, McKenna SP, Whalley D. The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol 1997; 36 (8): 878-83
37. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23 (2): 13745
38. Bruce B, Fries JF. The Stanford health assessment questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003; 30 (1): 167-78
39. Buchbinder R, Bombardier C, Yeung M, Tugwell P. Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures' responsiveness to treatment in a randomized controlled trial. Arthritis Rheum 1995; 38 (11): 1568-80
40. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986; 25 (2): 206-9
41. Leigh JP, Fries JF, Parikh N. Severity of disability and duration of disease in rheumatoid arthritis. J Rheumatol 1992; 19 (12): 1906-11
42. Wolfe F, Pincus T. Standard self-report questionnaires in routine clinical and research practice - an opportunity for patients and rheumatologists. J Rheumatol 1991; 18 (5): 643-6
43. Ramey DR, Raynauld JP, Fries JF. The Health Assessment Questionnaire 1992: status and review. Arthritis Care Res 1992; 5 (3): 119-29
44. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9 (5): 789-93
45. Kosinski M, Kujawski SC, Martin R, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002; 8 (3): 231-40
46. Pincus T, Summey JA, Soraci Jr SA, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983; 26 (11): 1346-53
47. Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985; 35 (273): 185-8
48. Essink-Bot M-L, Krabbe PF, Bonsel GJ, Aaronson NK. An empirical comparison of four generic health status measures: The Nottingham Health Profile, the Medical Outcomes Study 36-item Short-Form Health Survey, the COOP/WONCA charts, and the EuroQol instrument. Med Care 1997; 35 (5): 522-37
49. Hunt SM, McKenna SP, McEwen J, Williams J, Papp E. The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med 1981; 15 (3 Pt 1): 221-9
50. Jenkinson C, Fitzpatrick R, Argyle M. The Nottingham Health Profile: an analysis of its sensitivity in differentiating illness groups. Soc Sci Med 1988; 27 (12): 1411-4
51. Wells G, Boers M, Shea B, et al. Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis: preliminary findings in the generic health OMERACT study. OMERACT/ILAR Task Force on Generic Quality of Life. Life Outcome Measures in Rheumatology. International League of Associations for Rheumatology. J Rheumatol 1999; 26 (1): 217-21
52. Houssien DA, McKenna SP, Scott DL. The Nottingham Health Profile as a measure of disease activity and outcome in rheumatoid arthritis. Br J Rheumatol 1997; 36 (1): 69-73
53. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305 (6846): 160-4
54. Carter WB, Bobbitt RA, Bergner M, Gilson BS. Validation of an interval scaling: the sickness impact profile. Health Serv Res 1976; 11 (4): 516-28
55. Sullivan M, Ahlmen M, Bjelle A. Health status assessment in rheumatoid arthritis. I. Further work on the validity of the Sickness Impact Profile. J Rheumatol 1990; 17 (4): 439-47
56. MacKenzie CR, Charlson ME, DiGioia D, Kelley K. Can the Sickness Impact Profile measure change? An example of scale assessment. J Chronic Dis 1986; 39 (6): 429-38
57. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30 (6): 473-83
58. McHorney CA, Ware Jr JE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32 (1): 40-66
59. Tuttleman M, Pillemer SR, Tilley BC, et al. A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group. J Rheumatol 1997; 24 (10): 1910-5
60. Talamo J, Frater A, Gallivan S, Young A. Use of the short form 36 (SF36) for health status measurement in rheumatoid arthritis. Br J Rheumatol 1997; 36 (4): 463-9
61. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE, Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43 (7): 1478-87
62. Singh A, Wanke LA, Parasuraman TV, Lubeck D. Reliability and validity of SF-36 vitality scale in measuring vitality of methotrexate-naive patients with early, active rheumatoid arthritis. Presented at American College of Rheumatology 2002
63. van Agt HM, Essink-Bot M-L, Krabbe PF, Bonsel GJ. Test-retest reliability of health state valuations collected with the EuroQol questionnaire. Soc Sci Med 1994; 39 (11): 1537-44
64. Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993; 2 (3): 169-80
65. The EuroQoL Group. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16 (3): 199-208
66. Hurst NP, Jobanputra P, Hunter M, Lambert M, Lochhead A, Brown H. Validity of EuroQol - a generic health status instrument - in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. Br J Rheumatol 1994; 33 (7): 655-62
67. Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br J Rheumatol 1997; 36 (7): 786-93
68. Macran S, Weatherly H, Kind P. Measuring population health: a comparison of three generic health status measures. Med Care 2003; 41 (2); 218-31
69. Kaplan RM, Anderson JP, Wu AW, Mathews WC, Kozin F, Orenstein D. The Quality of Well-being Scale. Applications in AIDS, cystic fibrosis, and arthritis. Med Care 1989; 27 Suppl. 3: S27-43
70. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics 1995; 7 (6): 490-502
71. Bombardier C and Raboud J. A comparison of health-related quality-of-life measures for rheumatoid arthritis research. The Auranofin Cooperating Group. Control Clin Trials 1991; 12 Suppl. 4: 243S-56S
72. Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 2003; 56 (4): 317-25
73. Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis. The Arthritis Impact Measurement Scales. Arthritis Rheum 1980; 23 (2): 146-52
74. Meenan RF, Gertman PM, Mason JH, Dunaif R. The Arthritis Impact Measurement Scales. Further investigations of a health status measure. Arthritis Rheum 1982; 25 (9): 1048-53
75. Anderson JJ, Firschein HE, Meenan RF. Sensitivity of a health status measure to short-term clinical changes in arthritis. Arthritis Rheum 1989; 32 (7): 844-50
76. Liang MH, Larson MG, Cullen KE, Schwartz JA. Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. Arthritis Rheum 1985; 28 (5): 542-7
77. Meenan RF, Mason JH, Anderson JJ, Guccione AA, Kazis LE. AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales Health Status Questionnaire. Arthritis Rheum 1992; 35 (1): 1-10
78. Pouchot J, Guillemin F, Coste J, Bregeon C, Sany J. Validity, reliability, and sensitivity to change of a French version of the Arthritis Impact Measurement Scales 2 (AIMS2) in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol 1996; 23 (1): 52-60
79. Archenholtz B, Bjelle A. Reliability, validity, and sensitivity of a Swedish version of the revised and expanded Arthritis Impact Measurement Scales (AIMS2). J Rheumatol 1997; 24 (7): 1370-7
80. Ware Jr JE, Keller SD, Hatoum HT, Kong SX. The SF-36 Arthritis-Specific Health Index (ASHI): I. Development and cross-validation of scoring algorithms. Med Care 1999; 37 Suppl. 5: MS40-50
81. Lubeck DP, Yelin E, Katz PP, Roepke L, Wanke L, Buatti M. Responsiveness to change of the SF-36 in RAPOLO, a longitudinal study of rheumatoid arthritis patients treated with etanercept. Value in Health 2001; 4 (2): 63
82. Lubeck DP, Yelin E, Katz PP, Roepke L, Wanke L, Buatti M. The correlation between arthritis specific measures and SF-36 scales in rheumatoid arthritis patients. Value in Health 2001; 4 (2)
83. Tugwell P, Bombardier C, Buchanan WW, Goldsmith CH, Grace E, Hanna B. The MACTAR Patient Preference Disability Questionnaire - an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. J Rheumatol 1987; 14 (3): 446-51
84. Tugwell P, Bombardier C, Buchanan WW. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires. Arch Intern Med 1990; 150: 59-62
85. Whalley D, McKenna SP, de Jong Z, van der Heijde D. Quality of life in rheumatoid arthritis. Br J Rheumatol 1997; 36 (8): 884-8
86. Tijhuis GJ, de Jong Z, Zwinderman AH, et al. The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire. Rheumatology 2001; 40 (10): 1112-9
87. Ditto PH, Druley JA, Moore KA, Danks JH, Smucker WD. Fates worse than death: the role of valued life activities in health-state evaluations. Health Psychol 1996; 15 (5): 332-43
88. Katz PP, Yelin EH, Lubeck DP, Wanke LA, Buatti MC. Satisfaction with function: what type of function do rheumatoid arthritis patients value most? Arthritis Rheum 2001; 44 Suppl. Abstract 793
89. Guzman J, Maetzel A, Peloso P, Yeung N, Bombardier C. Disability scores in DMARD trials: What is a clinically important change? Arthritis Rheum 1996; 3 Suppl.: 208
90. Singh A, Sato R, Wanke L. How much improvement in functioning is considered important by patients with active refractory rheumatoid arthritis. Ann Rheum Dis 2003; 62 Suppl. 2: 108
91. Kosinski M, Martin R, Henkenius S, Wanke LA, Buatti M. Determining clinically meaningful improvement in SF-36 scale scores for treatment studies in rheumatoid arthritis. Arthritis Rheum 2000; 43 Suppl.: 140
92. Doyle JJ. Economic and quality-of-life impact of rheumatoid arthritis. Managed Care 2001; 10 Suppl.: 15-18
93. Wells G, Anderson J, Beaton D, et al. Minimal clinically important difference module: summary, recommendations, and research agenda. J Rheumatol 2001; 28 (2): 452-4
94. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20 (3): 557-60
95. Redelmeier DA, Lorig K. Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med 1993; 153 (11): 1337-42
96. Singh G, Sato R, Parasuraman TV, Wanke L, Wyeth Research, Amgen. How much improvement in functional status is considered important by patients with MTX-naïve early rheumatoid arthritis: a comparison with DMARD-refractory patients. Presented at the ACR/ARHP Annual Scientific Meeting 2003, October 24-28, 2003; Florida.